{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:38:04Z","timestamp":1778801884529,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To achieve the best treatment of heart failure, it is important to use all recommended drugs at their target doses. Given that underuse of medications can occur in individuals with cognitive impairment, we investigated the filled prescriptions and target doses of heart failure medication for older individuals with and without cognitive impairment as well as associated factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study was based on two separate datasets. The first dataset, which was based on data from questionnaires sent to nursing homes in Sweden, included 405 individuals with heart failure. The data were linked with the Swedish Prescribed Drug Register and the National Patient Register to obtain information regarding filled prescriptions of heart failure medications and heart failure diagnoses among the population. In the second dataset, medical records of individuals aged 75 years or older admitted to a hospital in northern Sweden were reviewed and individuals with heart failure were identified. Target doses of heart failure medications were evaluated in 66 individuals who lived at home.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Filled prescriptions of mineralocorticoid receptor antagonists and loop diuretics were significantly more common in individuals without cognitive impairment (OR 1.087; 95% CI 1.026\u20131.152, p\u2009&lt;\u20090.05) and (OR 1.057; 95% CI 1.017\u20131.098, p\u2009&lt;\u20090.05), respectively. There were no significant differences between individuals with and without cognitive impairment in terms of achieving target doses for any of the drug classes. A higher age was associated with fewer filled prescriptions and less ability to reach the target doses of beta blockers (OR 0.950; 95% CI 0.918\u20130.984, p\u2009&lt;\u20090.05) and (OR 0.781; 95% CI 0.645\u20130.946, p\u2009&lt;\u20090.05), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggest that individuals with cognitive impairment are partly undertreated for heart failure in that they had fewer filled prescriptions of important heart medications. Separately, the relatively low proportion of older individuals reaching target doses is an important observation and indicates that treatment of heart failure could be further optimised among older individuals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-023-04223-3","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T08:06:46Z","timestamp":1693296406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of heart failure medications in older individuals and associations with cognitive impairment"],"prefix":"10.1186","volume":"23","author":[{"given":"Linnea","family":"Abramsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-2900","authenticated-orcid":false,"given":"Annica","family":"Backman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-4780","authenticated-orcid":false,"given":"Hugo","family":"L\u00f6vheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-2327","authenticated-orcid":false,"given":"David","family":"Edvardsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3615-4880","authenticated-orcid":false,"given":"Maria","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"4223_CR1","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, ESC Scientific Document Group., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, 2021;42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"4223_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"4223_CR3","doi-asserted-by":"publisher","first-page":"60A","DOI":"10.1016\/s0002-9149(88)80087-0","volume":"62","author":"K Swedberg","year":"1988","unstructured":"Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol. 1988;62(2):60A\u20136. https:\/\/doi.org\/10.1016\/s0002-9149(88)80087-0. PMID: 2839019.","journal-title":"Am J Cardiol"},{"key":"4223_CR4","first-page":"23122318","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation. 1999;100:23122318.","journal-title":"ATLAS Study Group Circulation"},{"key":"4223_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, et al. Carvedilol prospective randomized cumulative survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651\u20138.","journal-title":"N Engl J Med"},{"key":"4223_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215\u201325.","journal-title":"Eur Heart J"},{"key":"4223_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"4223_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"4223_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"4223_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al. CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772\u20136.","journal-title":"Lancet"},{"key":"4223_CR11","doi-asserted-by":"publisher","unstructured":"Faris R, Flather M, Purcell H et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002;82(2):149\u201358. https:\/\/doi.org\/10.1016\/s0167-5273(01)00600-3. PMID: 11853901.","DOI":"10.1016\/s0167-5273(01)00600-3"},{"key":"4223_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, et al. SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet"},{"key":"4223_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ejhf.1160","volume":"20","author":"AH Abdul-Rahim","year":"2018","unstructured":"Abdul-Rahim AH, Shen L, Rush CJ, et al. VICCTA Heart failure collaborators. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail. 2018;20:1139\u201345.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"4223_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/pds.4430","volume":"27","author":"S El Hadidi","year":"2018","unstructured":"El Hadidi S, Darweesh E, Byrne S, et al. A tool for assessment of heart failure prescribing quality: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2018;27(7):685\u201394. https:\/\/doi.org\/10.1002\/pds.4430.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"4223_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13561820.2015.1027334","volume":"29","author":"ME Crissinger","year":"2015","unstructured":"Crissinger ME, Marchionda KM, Dunlap ME. Adherence to clinical guidelines in heart failure (HF) outpatients: impact of an interprofessional HF team on evidence-based medication use. J Interprof Care. 2015;29(5):483\u20137. https:\/\/doi.org\/10.3109\/13561820.2015.1027334.","journal-title":"J Interprof Care"},{"issue":"8","key":"4223_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2013.06.004","volume":"19","author":"M McCarren","year":"2013","unstructured":"McCarren M, Furmaga E, Jackevicius CA, et al. Improvement of guideline \u03b2-blocker prescribing in heart failure: a cluster-randomized pragmatic trial of a pharmacy intervention. J Card Fail. 2013;19(8):525\u201332. https:\/\/doi.org\/10.1016\/j.cardfail.2013.06.004.","journal-title":"J Card Fail"},{"issue":"8","key":"4223_CR17","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s11606-021-06901-7","volume":"36","author":"L Gilstrap","year":"2021","unstructured":"Gilstrap L, Austin AM, O\u2019Malley AJ, et al. Association between Beta-Blockers and Mortality and Readmission in older patients with heart failure: an instrumental variable analysis. J Gen Intern Med. 2021;36(8):2361\u20139. https:\/\/doi.org\/10.1007\/s11606-021-06901-7.","journal-title":"J Gen Intern Med"},{"key":"4223_CR18","first-page":"209","volume":"2","author":"GA Heckman","year":"2007","unstructured":"Heckman GA, Patterson CJ, Demers C, et al. Heart failure and cognitive impairment: challenges and opportunities. Clin Interv Aging. 2007;2:209\u201318.","journal-title":"Clin Interv Aging"},{"issue":"6","key":"4223_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cardfail.2017.04.007","volume":"23","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Moffitt P, Perez-Moreno AC, et al. Cognitive impairment and heart failure: systematic review and Meta-analysis. J Card Fail. 2017;23(6):464\u201375. https:\/\/doi.org\/10.1016\/j.cardfail.2017.04.007.","journal-title":"J Card Fail"},{"key":"4223_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/00009373927","volume":"22","author":"M Lopponen","year":"2006","unstructured":"Lopponen M, Raiha I, Isoaho R, et al. Dementia associates with undermedication of cardiovascular diseases in the elderly: a population-based study. Dement Geriatr Cogn Disord. 2006;22:132\u201341. https:\/\/doi.org\/10.1159\/000093739.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"4223_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/pds.878","volume":"12","author":"I Klarin","year":"2003","unstructured":"Klarin I, Fastbom J, Wimo A. A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. Pharmacoepidemiol Drug Saf. 2003;12:669\u201378. https:\/\/doi.org\/10.1002\/pds.878.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"4223_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00228-017-2249-8","volume":"73","author":"M Gustafsson","year":"2017","unstructured":"Gustafsson M, Sj\u00f6lander M, Pfister B, et al. Pharmacist participation in hospital ward teams and hospital readmissions rates among people with dementia - a randomized controlled trial. Eur J Clin Pharmacol. 2017;73(7):827-835. https:\/\/doi.org\/10.1007\/s00228-017-2249-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"4223_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstr\u00f6m","year":"2001","unstructured":"Burstr\u00f6m K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621\u201335.","journal-title":"Qual Life Res"},{"key":"4223_CR24","first-page":"120","volume":"2","author":"PO Sandman","year":"1988","unstructured":"Sandman PO, Adolfsson R, Norberg A, et al. Long-term care of the elderly. A descriptive study of 3600 institutionalized patients in the county of Vasterbotten, Sweden. Compr Gerontol A. 1988;2:120\u201332.","journal-title":"Compr Gerontol A"},{"key":"4223_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0447.1981.tb00670.x","volume":"63","author":"R Adolfsson","year":"1981","unstructured":"Adolfsson R, Gottfries CG, Nystrom L, et al. Prevalence of dementia disorders in institutionalized swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand. 1981;63:225\u201344.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"4223_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"key":"4223_CR27","unstructured":"World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems (ICD-10). 10th Revision. 2019. [cited 2022-05-18]. https:\/\/icd.who.int\/browse10\/2019\/en#\/I50.0."},{"key":"4223_CR28","doi-asserted-by":"publisher","first-page":"e036650","DOI":"10.1136\/bmjopen-2019-036650","volume":"10","author":"J Kindstedt","year":"2020","unstructured":"Kindstedt J, Svahn S, Sj\u00f6lander M, et al. Investigating the effect of clinical pharmacist intervention in transitions of care on drug-related hospital readmissions among the elderly: study protocol for a randomised controlled trial. BMJ Open. 2020;10:e036650. https:\/\/doi.org\/10.1136\/bmjopen-2019-036650.","journal-title":"BMJ Open"},{"key":"4223_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3233\/JAD-190599","volume":"72","author":"H L\u00f6vheim","year":"2019","unstructured":"L\u00f6vheim H, Gustafsson M, Isaksson U, et al. Gottfries\u2019 cognitive scale for staff proxy rating of cognitive function among nursing home residents. J Alzheimers Dis. 2019;72:1251\u201360.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"4223_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1365-2753.2009.01169.x","volume":"16","author":"C Mahler","year":"2010","unstructured":"Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (Mars) in Germany. J Eval Clin Pract. 2010;16(3):574\u20139. https:\/\/doi.org\/10.1111\/j.1365-2753.2009.01169.x.","journal-title":"J Eval Clin Pract"},{"key":"4223_CR31","unstructured":"V\u00e4sterbottens County Councils guidelines. (2022). https:\/\/regionvasterbotten.se\/for-vardgivare\/behandlingsstod-och-vardriktlinjer\/lakemedel\/behandlingsrekommendationer\/terapirekommendationer."},{"key":"4223_CR32","unstructured":"Janusinfo. Cardiovascular therapy area. Assessed 2022-05-12. https:\/\/klokalistan.se\/terapiomrade\/hjarta-och-karl.html."},{"key":"4223_CR33","unstructured":"Mayo Clinic. Bradycardia. Assessed 2022-05-12. https:\/\/www.mayoclinic.org\/diseases-conditions\/bradycardia\/symptoms-causes\/syc-20355474#:~:text=If%20you%20have%20bradycardia%2\u00a0C%20your,weak%2\u00a0C%20and%20short%20of%20breath."},{"key":"4223_CR34","unstructured":"National Health Service., NHS. Low blood pressure (hypotension). England. Assessed 2022-05-12. https:\/\/www.nhs.uk\/conditions\/low-blood-pressure-hypotension\/."},{"key":"4223_CR35","unstructured":"Gaieski D, Mikkelsen M, UpToDate. Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock. Topic 98976, version 32.0. [updated 2022-05-09; cited 2022-05-12]. https:\/\/www.uptodate.com\/contents\/evaluation-of-and-initial-approach-to-the-adult-patient-with-undifferentiated-hypotension-and-shock?search=hypotension%20%20&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2."},{"issue":"2","key":"4223_CR36","first-page":"81","volume":"32","author":"GRD Jones","year":"2011","unstructured":"Jones GRD. Estimating renal function for drug dosing decisions. Clin Biochem Rev. 2011;32(2):81\u20138.","journal-title":"Clin Biochem Rev"},{"issue":"4","key":"4223_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00228-019-02778-y","volume":"76","author":"S Svahn","year":"2020","unstructured":"Svahn S, L\u00f6vheim H, Isaksson U, et al. Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden. Eur J Clin Pharmacol. 2020;76(4):525\u201337. https:\/\/doi.org\/10.1007\/s00228-019-02778-y.","journal-title":"Eur J Clin Pharmacol"},{"issue":"19","key":"4223_CR38","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","volume":"29","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, ESC Committee for Practice Guidelines (CPG), et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of Acute and Chronic Heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388\u2013442. https:\/\/doi.org\/10.1093\/eurheartj\/ehn309.","journal-title":"Eur Heart J"},{"issue":"8","key":"4223_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, ESC Committee for Practice Guidelines, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of Acute and Chronic Heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803\u201369. https:\/\/doi.org\/10.1093\/eurjhf\/hfs105.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"4223_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijcard.2007.10.010","volume":"10","author":"M Fu","year":"2008","unstructured":"Fu M. Beta-blocker therapy in heart failure in the elderly. Int J Cardiol. 2008;10(2):149\u201353. https:\/\/doi.org\/10.1016\/j.ijcard.2007.10.010.","journal-title":"Int J Cardiol"},{"key":"4223_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijcard.2016.06.178","volume":"1","author":"JA Franco Pel\u00e1ez","year":"2016","unstructured":"Franco Pel\u00e1ez JA, Cort\u00e9s Garc\u00eda M, et al. Relationship between different doses of beta-blockers and prognosis in elderly patients with reduced ejection fraction. Int J Cardiol. 2016;1:220:219\u201325. https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.178.","journal-title":"Int J Cardiol"},{"issue":"2","key":"4223_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5830\/CVJA-2019-001","volume":"23","author":"J Bolon","year":"2019","unstructured":"Bolon J, McCutcheon K, Klug E, et al. Beta-blocker target dosing and tolerability in a dedicated heart failure clinic in Johannesburg. Cardiovasc J Afr. 2019;23(2):103\u20137. https:\/\/doi.org\/10.5830\/CVJA-2019-001.","journal-title":"Cardiovasc J Afr"},{"issue":"6","key":"4223_CR43","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/HJH.0000000000002374","volume":"38","author":"A Cremer","year":"2020","unstructured":"Cremer A, Boutouyrie P, Laurent S, et al. Orthostatic hypotension: a marker of blood pressure variability and arterial stiffness: a cross-sectional study on an elderly population: the 3-City study. J Hypertens. 2020;38(6):1103\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000002374.","journal-title":"J Hypertens"},{"issue":"6","key":"4223_CR44","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","volume":"72","author":"MR Weir","year":"2018","unstructured":"Weir MR, Lakkis JI, Jaar B, et al. Use of Renin-Angiotensin System Blockade in Advanced CKD: an NKF-KDOQI Controversies Report. Am J Kidney Dis. 2018;72(6):873\u201384. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.010.","journal-title":"Am J Kidney Dis"},{"key":"4223_CR45","unstructured":"Swedish Agency for Health Technology Assessment and Assessment of Social Services. Estimate of Renal Function. A systematic literature review. SBU. ; 2012. Assessed 2022-05-09. https:\/\/www.sbu.se\/contentassets\/8f432cbce7ad454dbf3040627371951a\/njurfunktion_141110.pdf."}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-04223-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-023-04223-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-04223-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:13:08Z","timestamp":1700302388000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-023-04223-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4223"],"URL":"https:\/\/doi.org\/10.1186\/s12877-023-04223-3","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Regarding dataset 1, informed consent was obtained from all subjects and\/or their legal guardian(s) using an opt-out procedure in accordance with the Swedish Ethical Review Law. Written information was provided to all participants and posters with information about the study was available by the entrance of the nursing homes. Residents and their relatives could decline to participate in the study. Ethical approval was obtained from the Swedish Regional Ethical Review Board (Dnr 2018\/145\u2009\u2212\u200931). Regarding dataset 2, people who fulfilled the inclusion criteria were given oral and written information about the study, and informed consent was obtained from those who wished to participate. Anyone who did not wish to participate was free to decline or withdraw at any time during the trial. In Sweden, the Ethical Review Law permits research involving persons with cognitive impairment under certain conditions, even though they cannot give a full informed consent. Individuals with major NCD participated without formal written informed consent, although in these cases both the intended participant and the next of kin were informed about the study and were given the opportunity to decline participation. This procedure of informing the intended participant and next of kin is approved by the Regional Ethical Review Board in Ume\u00e5, Sweden, registration number Dnr 2017-69-31\u00a0M, 2018-83-32\u00a0M, and 2018-254-32\u00a0M). All methods were carried out in accordance with the Helsinki declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"524"}}